艾美捷科技代理BioGenex品牌产品。

Biogenex位于美国旧金山，是抗原修复的发明者，是致力于研发生产准确、可靠、可重复性的高效检测方法的自动化和标准化的先驱。BioGenex拥有全面的免疫组化全自动处理系统，包括i1000抗原修复系统、i6000自动染色仪、iVISION数码成像分析系统等，具有检测诊断的高度一致性，为科研和临床诊治提供高质量的参考依据。Biogenx i 系列免疫组化全自动处理系统是使您的科研和临床病理诊断国际化的最佳途径。

BioGenex is a global market leader and an innovator in providing customer-centric molecular pathology solutions and complete walk-away automation of cell and tissue staining. We develop, manufacture and market automated slide-based staining instruments and offer a broad range of histology products for immunohistochemistry (IHC), in-situ hybridization (ISH), miRNA, in situ PCR.

BioGenex的主要产品包括：

（1）IHC

Automation

Primary Antibodies

Antigen Retrieval & Dewax

Detection Systems

Controls

Ancillaries

（2）ISH/CISH

Automation

ISH/CISH Probes

Nucleic Retrieval & Dewax

Detection Systems

Ancillaries

（3）FISH

eFISH Automation

eFISH Probes

Nucleic Retrieval & Dewax

eFISH Visualization Kits

eFISH Ancillaries

（4）miRNA

miRNA Automation

miRNA Probes & Controls

Nucleic Retrieval & Dewax

Detection Systems

Ancillaries

（5）Multiplexing & Double Staining

Automation

Antibody Cocktails

Multiplexing

Antigen Retrieval & Dewax

Detection Systems

Ancillaries

（6）Special Stains

Automation

Special Stains

Ancillaries

（7）In Situ PCR

（8）1IF

GeneTex公司致力于研究和开发各种基础医学相关的新型研究用抗体。公司起初的核心目标是帮助科学家寻找引发人类乳腺癌的分子新靶标，现在已经逐步扩展到其他研究领域新抗体和配套诊断试剂的开发。至今，癌症研究相关抗体已经成为了该公司的特色产品。Genetex 公司以获得客户100%的满意度为目标，曾与多家著名抗体公司合作业务。目前抗体总数已逾50,000种，且每月推出近400种新抗体。

With a 20-year history of quality results, GeneTex sets itself apart from other antibody companies by taking the necessary steps to properly validate our antibodies. Antibody validation remains an industry-wide challenge with ramifications that can impact progress in the life sciences and medicine.

GeneTex的主要产品包括：

Primary Antibodies

Secondary Antibodies

Proteins & Peptides

Lysates & Slides

Serum & Reagents

Research Kits

Isotype Controls

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

Dendritics公司主要关注人类树突状细胞，希望找到能够促使CD34+造血前体细胞转化为树突状细胞（在GM-CSF和TNF-alpha存在的情况下）的细胞因子。在1992-2005年间，大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。

DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.

Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.

The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com